The aim of this study was to assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) in the treatment of COPD.
Rogliani, P., Calzetta, L., Braido, F., Cazzola, M., Clini, E., Pelaia, G., et al. (2018). LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. INTERNATIONAL JOURNAL OF COPD, 13, 3115-3130 [10.2147/COPD.S170606].
LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
Rogliani P.
;Calzetta L.;Cazzola M.;
2018-01-01
Abstract
The aim of this study was to assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) in the treatment of COPD.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
